Given the unforeseen/unanticipated use of nerve agents in the battlefield and on the homeland, military personnel can benefit from this oncedaily pretreatment. It may also be desirable to pretreat certain medical and emergency aid personnel following a known/suspected nerveagent attack. Also, a novel, improved PB extended release formulations can be commercialized for the treatment of myasthenia gravis.
